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G enitourinary tract infections are the most preva-lent type of bacterial infection [1 , 2].  
Fluoroquinolones (FQs) are commonly used to treat 
genitourinary tract infections [3].  Recently,  the inci-
dence of FQ-resistant Escherichia coli (E. coli) and 
extended-spectrum beta-lactamase (ESBL)-producing 
E. coli,  both of which are major pathogenic bacteria of 
genitourinary tract infections,  has been increasing 
[4 , 5].  The susceptibility rate of E. coli to levofloxacin 
(LVFX; minimum inhibitory concentration [MIC] 
≤ 2 μg/mL) in Japan decreased from 91.9% in 2000 to 
63.4% in 2016 [5].  In contrast,  sitafloxacin (STFX) 
(sitafloxacin hydrate: GracevitⓇ,  Daiichi-Sankyo,  
Tokyo,  Japan),  a new quinolone approved in 2008,  has 
shown strong antibacterial activity against FQ-resistant 
E. coli and ESBL-producing E. coli [6].  STFX is currently 
approved only in Japan.  The susceptibility rate (MIC 
≤ 1 μg/mL) has been maintained at 87.3% since 2016.  
Quinolones exhibit antimicrobial activity by inhibiting 
DNA replication by acting on bacterial DNA gyrase and 
topoisomerase IV.  Resistance to quinolones increases in 
accumulation of genetic mutations that encode the sub-
units of these target enzymes.  Compared with other 
quinolones,  STFX showed the highest inhibitory activ-
ity against mutant target enzymes of E. coli with quino-
lone-resistant mutations.  It is therefore widely used for 
the treatment of genitourinary tract infections,  includ-
ing severe,  refractory,  recurrent,  and suspected infec-
tions caused by antibiotic-resistant bacteria [1].  The 
Japanese guidelines for genitourinary tract infections 
recommend STFX as the front-line treatment for com-
plicated cystitis,  acute pyelonephritis,  prostatitis,  and 
epididymitis [7].  The dose of STFX for patients with 
refractory genitourinary tract infections is usually 100 
or 200 mg daily.  The former is given as 50 mg twice 
daily or 100 mg once daily,  whereas the latter is approved 
only on a schedule of 100 mg twice daily; once daily is 
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off-label.  For quinolone antibacterial agents,  it is con-
sidered more effective to increase the peak blood con-
centration (Cmax) from the perspective of pharmaco-
kinetic/pharmacodynamic (PK/PD) theory [8, 9].  
Regarding PK/PD parameters for FQ efficacy,  the esti-
mated values against Gram-negative rods are area under 
the concentration−time curve (AUC)/MIC = 100 and 
Cmax/MIC = 8 [10].  In our previous study,  STFX 
100 mg once daily was effective only when the MIC was 
less than 0.25 μg/mL [11].  However,  we also demon-
strated that the simulated PK/PD target value of STFX 
200 mg once daily,  analyzed by the MULTI program,  
was effective for pathogens with an STFX MIC less than 
0.5 μg/mL [11].  Therefore,  we suggest that there is 
room for debate regarding the optimal administration 
schedule of STFX 200 mg daily.  In addition,  we believe 
that decreasing the frequency of daily oral intake is use-
ful for patient compliance [12],  which might lead to the 
prevention of antimicrobial resistance.
In this clinical trial,  we will evaluate the clinical effi-
cacy and safety of STFX 200 mg once daily (QD) for 
7 days,  which thus far has been off-label by the 
Japanese Ministry of Health,  Labor and Welfare,  in 
patients with refractory genitourinary tract infections 
including recurrent and complicated cases.
Endpoints
The primary endpoint is the microbiological efficacy 
at 5-9 days after the last administration of STFX.  
Efficacy is defined as a negative urine culture 
(< 104 CFU mL).  Secondary endpoints are the clinical 
efficacies at different time points (during treatment,  
and 5-9 and 28-42 days after treatment completion) and 
adverse effects.  Clinical efficacy is evaluated using the 
Core Lower Urinary Tract Symptom Score (CLSS) 
(Table 1) [13].  A clinical cure is defined as the absence 
of symptoms.  Adverse events are evaluated with blood 
tests and medical interviews (i.e.,  through questions 
about diarrhea and headache) before treatment,  during 
treatment,  and 5-9 days after treatment completion.  
These endpoints are based on the latest Japanese clinical 
guidelines for genitourinary tract infections [14].  
Eligibility Criteria
Patients with refractory genitourinary tract infec-
tions will be recruited between February 2021 and 
October 2022 at Okayama University Hospital.  All 
patients will provide written informed consent to par-
ticipate in this study with full understanding of the 
study procedures.
The inclusion criteria are as follows: aged ≥ 20 years 
and with fever ≥ 37.5°C or costovertebral angle tender-
ness,  or any cystitis symptoms,  such as micturition 
pain,  urinary frequency,  urgency,  and lower abdomi-
nal pain with pyuria.  Thus,  adult patients diagnosed 
with refractory genitourinary tract infections,  including 
recurrent or complicated cystitis,  complicated pyelone-
phritis,  bacterial prostatitis,  and epididymitis,  will be 
enrolled.  Pyuria is defined as ≥ 10 white blood cells 
(WBCs)/μL counted by flow cytometric analysis; ei-
ther ≥ 10 WBCs/mm3 counted in a counting chamber or 
a positive leucocyte esterase result using urine test 
paper with uncentrifuged urine; or ≥ 5 WBCs/high-
power field (hpf) in the sediment of centrifuged urine.  
Exclusion criteria are as follows: a previous episode 
of quinolone hypersensitivity; a history of allergic 
asthma or hives; current pregnancy,  lactation,  epi-
lepsy,  myasthenia gravis,  aortic dissection,  renal fail-
ure,  indwelling urinary catheter,  or clean intermittent 
catheterization; or judged as ineligible by investigators 
because of low compliance.  Furthermore,  a dropout 
will be recorded if live bacteria < 105 CFU/mL are 
detected in midstream urine before administration of 
STFX.
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Table 1　 Core Lower Urinary Tract Symptom Score (CLSS).
How many times do you typically urinate?
1 Daytime frequency 0 1 2 3≤7 8～9 10～14 ≥15
2 Nocturia 0 1 2 30 1 2～3 ≥4
How often do you have the following symptoms?
never rarely sometimes often
3 Urgency 0 1 2 3
4 Urgency incontinence 0 1 2 3
5 Stress incontinence 0 1 2 3
6 Slow stream 0 1 2 3
7 Straining 0 1 2 3
8 Incomplete emptying 0 1 2 3
9 Bladder pain 0 1 2 3
10 Urethral pain 0 1 2 3
Treatment Methods
This is a single-arm trial.  After being assessed for 
eligibility,  participants are given STFX 200 mg once daily 
for 7 days.  The test antimicrobials are four 50-mg STFX 
tablets administered orally once daily (200 mg/day).  
Figure 1 shows the protocol.  Urinalysis is performed at 
the first visit,  5-9 days after starting treatment,  and 
5-9 days following treatment completion.  Urine cul-
tures and blood tests are performed at the first visit and 
5-9 days following treatment completion.  The CLSS 
sheet is completed at the first visit and 5-9 days and 
28-42 days following treatment completion.  
Statistical Consideration
Data management. Data will be collected during 
the observation period by the research staff.  Data entry 
into the database will be completed and monitored by 
the data manager.  The data sheet will include the fol-
lowing information: age,  gender,  body mass index,  
type of genitourinary tract infection,  medical history,  
history of recurrent urinary tract infections for the past 
12 months,  data on urinalysis and urine culture,  data 
on blood tests (e.g.,  serum creatinine,  aspartate,  and 
alanine aminotransferase),  and microbiological and 
clinical efficacy.
Sample size calculation. The required sample size 
is calculated for an expected response rate of 90%,  and 
the threshold response rate is 80%,  with a statistical 
power of 80% and an alpha error of 5%.  Assuming a 
dropout rate of 10%,  the target number of patients is set 
at 92.  
Statistical analysis. Depending on data normal-
ity,  continuous data will be presented as either the 
mean and standard deviation or the median and inter-
quartile range.  We will compare the data with an his-
torical control group using either the Mann−Whitney 
U test or a Chi-square test.  For categorical variables,  
the data will be presented as counts and percentages and 
then analyzed with Fisher’s exact test.  Statistical signif-
icance will be confirmed at p < 0.05 for all analyses.  
Statistical analyses will be performed with EZR version 
1.36 (Saitama Medical Center,  Jichi Medical University,  
Saitama,  Japan),  a graphical user interface for R [15].
Conclusions
In this clinical trial,  we will evaluate the clinical effi-
cacy and safety of STFX 200 mg once daily (QD) for 
7 days in patients with refractory genitourinary tract 
infections.  If we confirm the clinical efficacy and safety 
of this regimen,  the Japanese Ministry of Health,  Labor 
and Welfare might approve the on-label use of STFX 
200 mg once daily (QD).
Ethics. This study was approved by the Okayama 
University Certified Review Board prior to initiation 
(Approval number CRB20-010).  The study is registered 
with the Japan Registry of Clinical Trials,  Japan 
(jRCTs061200052).  The participants reviewed the study 
documents and received individual counseling prior to 
providing written consent.











Allowable range (days) －2～0 －2～+2 －2～+2 －7～+7
Administration status ○
Adverse event ○ ○
Temperature ○ ○ ○ ○
Symptoms ○ ○ ○ ○
Urinalysis ○ ○ ○
Blood tests ○ ○ ○
Urine culture ○ ○
○,  Must be done; ○,  Depending on the situation.
Fig. 1　 Protocol of examinations.
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